You are here

Recursion

Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline

Fierce Biotech

Mon, 05/5/25 - 11:24 am

artificial intelligence

Recursion CEO launches pre-seed fund in response to NIH cuts

BioPharma Dive

Wed, 02/19/25 - 09:51 pm

Recursion's phase 2 brain disease trial yields scant evidence of efficacy

Fierce Biotech

Tue, 09/3/24 - 11:15 am

clinical trials

cerebral cavernous malformation

Recursion, Exscientia, and AI drug discovery’s moment of truth

Pharmaphorum

Thu, 08/15/24 - 11:29 am

artificial intelligence

AI biotechs Exscientia and Recursion agree to $688m merger

Pharmaphorum

Thu, 08/8/24 - 11:20 am

artificial intelligence

drug development

NVIDIA Doubles Down on AI Drug Discovery with $50M Recursion Investment

BioSpace

Wed, 07/12/23 - 11:05 pm

artificial intelligence